OBJECTIVE: To study the effect of¯uoxetine, a speci®c serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight. RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled trial, insulin-mediated glucose disposal was measured in 12 obese patients with NIDDM on diet alone before and after four weeks of treatment with either placebo (n 6) or¯uoxetine (n 6) at a dose level of 60 mg once a day. Insulin-mediated glucose disposal was assessed by the 2-step euglycemic hyperinsulinemic clamp technique. Patients were instructed on a weightmaintaining diet. RESULTS: Insulin infusion at 40 mU ? m 72 ? min 71 resulted in insulin levels of 720670 pmol ? L 71 with a mean plasma glucose value of 6.460.2 mmol ? L 71 . Compared to placebo,¯uoxetine increased glucose disposal (M) by 2.4-fold (P`0.05), the insulin sensitivity index (M/I) by 2.7-fold (P`0.03) and the glucose metabolic clearance rate (MCR) by 2.9-fold (P`0.03). Insulin infusion at 400 mU ? m 72 ? min 71 elicited insulin levels of 12 94761 512 pmol ? L 71 with a mean plasma glucose value of 5.660.4 mmol ? L 71 . Compared to placebo,¯uoxetine increased M by 30% (P NS), M/I by 40% (P`0.04) and MCR by 23% (P`0.04). Patient weight remained stable throughout the study with no change in dietary intake. CONCLUSION: Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss.
Introduction
Insulin resistance is one of the major abnormalities in the development of non-insulin-dependent diabetes mellitus (NIDDM) 1 Therefore, in the treatment of type II diabetes, the rationale is to use new drugs which improve insuline sensitivity. We have already shown that fen¯uramine, a serotonin agonist, improves plasma glucose in obese NIDDM patients without any change in plasma insulin or body weight. 2 More recently, it has been demonstrated that fen¯ur-amine exerts a direct effect on insulin sensitivity in obese NIDDM subjects. 3 Fluoxetine, another serotonin agonist, is currently used in the treatment of depression. 4 Its administration results in a centrally-mediated and highly selective inhibition of pre-synaptic 5-hydroxytryptamine reuptake. 5 While this medication is currently administered as an antidepressant, it has been shown to possess anorectic properties and can induce signi®cant weight reduction. 6, 7 We, as others, have previously demonstrated that in obese patients with NIDDM, uoxetine is ef®cient in producing weight loss and decreasing plasma glucose as well as insulin concentrations and glycosylated hemoglobin. 8±11 It is not clear, however, whether these effects are due to a direct action of the drug or are secondary to weight loss. Like fen¯uramine, 2,3,12,13¯u oxetine may impact on insulin-mediated glucose disposal independently of its effect on body weight. To answer this question, we examined, in a double-blind, placebo-controlled trial, the in¯uence of¯uoxetine on insulin sensitivity in obese weight-stable patients with NIDDM.
Research design and methods

Patient selection
Twelve obese volunteers with NIDDM were recruited for the study. NIDDM was de®ned according to National Diabetes Data Group criteria, 14 and only patients treated with diet alone were included. Obesity was characterized by a body mass index over 27 kg Á m 72 . All subjects were weight stable, in good general health and free of major vascular complications. None was taking medications known to affect carbohydrate metabolism. The study was approved by the Ethics Committee, and all subjects gave their informed consent voluntarily.
Study design
This randomized, parallel, double-blind, placebo-controlled trial was preceded by a run-in period of 1 month during which all volunteers were given placebo in a single-blind fashion. The patients were then randomly assigned to either¯uoxetine (n 6) or placebo (n 6) taken as 60 mg capsule per day in the morning. They were advised to maintain their body weight and were seen weekly. When necessary, caloric intake was adjusted to maintain a constant weight. Daily energy intake and dietary macronutrient content were assessed by a dietician at entry ad at the end of the study period. Compliance with treatment was ascertained in all patients by interview and pill count.
Euglycemic hyperinsulinemic clamp
Insulin sensitivity was measured in all patients with the euglycemic hyperinsulinemic clamp, as described by DeFronzo et al., 15 at the end of the placebo run-in period and after the four week treatment period. The study began at 8:00 am after an overnight fast. Patients were given their usual dose of¯uoxetine or placebo upon admission. A double-lumen intravenous catheter was inserted in an antecubital vein prior to initiation of the experiment and each patient was connected to a Biostator# (Model 3000 S/N, Life Science Instruments, Miles Laboratories Inc., Etobicoke, Ontario). Blood was drawn from a contralateral hand vein warmed at 68 C. Plasma glucose concentrations were ®rst brought slowly to normal using an internal algorithm included with the Biostator#. After a 2 h equilibration period, the 2-step hyperinsulinemic euglycemic clamp was initiated. Insulin was ®rst infused at a constant rate of 40 mU Á m 72 Á min 71 for 120 minutes and at 400 mU Á m 72 Á min 71 for another 120 min while plasma glucose was maintained at or near 5.6 mmol/L with a variable infusion of 20% dextrose using the Biostator#. Blood glucose was measured continuously with the Biostator# and blood samples were drawn from the contralateral arm at 10 min intervals over the last 30 min of each insulin step. The amount of exogenous glucose infused (M) during each step was calculated from the last 30 min of each 120 min infusion period. The insulin sensitivity index (M/I) was calculated by dividing the amount of glucose infused (M) by the mean insulin concentration during the same period of the clamp. Similarly, the glucose metabolic clearance rate (MCR) was calculated by dividing the amount of glucose infused (M) by the plasma glucose concentrations achieved during each insulin step. Even if glucose and insulin concentrations were constant by design, M/I and MCR were calculated to take into account small discrepancies in glucose or insulin concentrations during the clamp studies.
Assays
Plasma glucose was measured by the hexokinase technique after deproteinization with 6% PCA. 14 Plasma insulin was quanti®ed with a standard commercial radioimmunoassay kit (NCS Diagnostics, Etobicoke, Ontario). Glycosylated hemoglobin was measured at the end of each study by fast protein liquid chromatography 16 .
Statistical analysis
All data are expressed as means AE s.e.m. The important analysis of this study is the comparison between the effects of¯uoxetine and placebo; therefore, the Mann±Whitney U rank sum test was performed on the difference between the two treatment groups (unpaired comparisons between treatment effects of the two groups). In this particular case, the null hypothesis is that both treatments have the same effect, so that the variability of differences will be the same regardless of which two treatments are being compared. To gain some more insight into the more speci®c effects of¯uoxetine, Wilcoxon signed rank tests were also done on within subject changes between baseline and the end of treatment for each variable (paired comparisons). Non-parametric statistics test hypotheses were used because the sample size was small and the distribution of the data was not normal. The results are expressed as means AE s.e.m. and are considered signi®cant at a P value less than 0.05.
Results
Comparison of groups at baseline
Of the 12 diabetic volunteers entered in the protocol, six were randomized to¯uoxetine treatment and six to placebo. Baseline characteristics of the two treatment groups before randomization are given in Table 1 and 2. There was no signi®cant difference between the two groups at baseline (P b 0.05 using the Mann±Whitney U-test). 
Effect of treatment
No weight loss occurred during the month study period. Furthermore, fasting plasma glucose, insulin concentrations and glycosylated hemoglobin did not change signi®cantly (Table 2) . Dietary assessment before and after treatment in each group did not show any signi®cant difference. The results of the euglycemic hyperinsulinemic clamp are illustrated in Table 3 and Figures 1, 2 and 3. Glucose and insulin concentrations during each step of the euglycemic hyperinsulinemic clamp were not different within or between each study group (Figure 1) . Furthermore, insulin resistance indices were comparable at baseline in each treatment group (P b 0.05). In the ®rst insulin step (40 mU Á m 72 Á min
71
), there was, however, a signi®cant difference between the effect of both treatments on insulin sensitivity as estimated by M, M/I and MCR (P`0.05). M increased by 2.4-fold after 1 month of¯uoxetine treatment from 11.1 AE 3.9 to 26.2 AE 6.7 mmol Á kg 71 Á min 71 while it decreased slightly (30%) in the placebo group. This apparent reduction of M in the placebo group was, however, not statistically signi®cant (P b 0.05). In addition, there was a 2.9-fold increase in MCR after¯uoxetine treatment; this change was signi®cantly different from placebo values (P`0.03). The increase in M in thē uoxetine-treated group did not reach statistical signi®cance because two volunteers were inadvertently clamped at baseline at a higher glucose level (accounting for the high plasma glucose level of 7.1 mmol Á L 71 in this group). At higher insulin concentrations (400 mU Á m 72 Á min
), MaI was signi®-cantly increased after¯uoxetine treatment compared to placebo (P`0.04). On the other hand, MCR increased signi®cantly within the¯uoxetine group from baseline to the end of treatment (paired comparison; P`0.04), but the difference between groups was not statistically signi®cant. Finally, though M tended to increase after¯uoxetine treatment (40.3 AE 6.8 to 51.7 AE 6.9 mmol Á kg 71 Á min 71 ), it did not reach signi®cance (Figure 2 and Table 3 ).
Patient compliance and side effects
Fluoxetine was well tolerated by the patients, and the reported adverse effects were not increased in thē uoxetine-treated group compared to placebo. Compliance to the medication was more than 80% throughout the study period. Changes were calculated as the value obtained at the end minus the value obtained at the beginning of each treatment period. The Mann±Whitney U rank sum test was used for between group comparisons (unpaired comparisons). Changes were calculated as the value obtained at the end minus the value obtained at the beginning of each treatment period. The Mann±Whitney U rank sum test was used for between group comparisons (unpaired comparisons). b P`0.04 compared to baseline using the Wilcoxon signed rank test for paired comparison. c Average of ®ve subjects because of heavy hemolysis and erroneously low insulin concentrations in one volunteer.
Discussion
The present study was designed to assess whether uoxetine could improve insulin sensitivity in obese NIDDM subjects, independently from its effect on body weight. A four-week parallel blinded design was preferred over a crossover design because of signi®-cant¯uoxetine tissue accumulation and the risk of seasonal changes in diet and physical activities. The data demonstrate that the drug improves insulinmediated glucose disposal without any change in body weight at lower (40 mU Á m 72 Á min
71
) and at higher (400 mU Á m 72 Á min
) insulin infusion rates. The primary event leading to improved insulin sensitivity still remains hypothetical. Fluoxetine had either a direct effect on insulin sensitivity or resulted in improved dietary compliance with better glycemic . Data are expressed as means AE s.e.m. *P`0.05 for changes during¯uoxetine vs placebo treatment.
Fluoxetine effect on insulin sensitivity? P Maheux et al control and enhancement of insulin action. The latter hypothesis is unlikely because there was no modi®ca-tion of body weight or macronutrient content of diet. Consequently, these observations support a direct and speci®c effect of¯uoxetine on insulin sensitivity which is independent of the anorectic property of the drug. This interpretation of the data is supported by the studies of Pestell et al. 13 and Scheen et al.
3 with fen¯uramine and dexfen¯uramine, respectively. They showed that both serotonin agonists improved insulin sensitivity at lower insulin concentrations ( $ 600 pmol Á L 71 ). Furthermore, Scheen et al.
3
reported that dexfen¯uramine also improved insulin sensitivity at higher insulin concentrations ( $ 4 800 pmol Á L 71 ). In our study,¯uoxetine had a bene®cial effect on insulin sensitivity at both low ( $ 700 pmol Á L 71 ) and high ( $ 12 000 pmol Á L 71 ) insulin concentrations (Figures 1, 2 , and Table 3 ). Potter van Loon et al. 17 similarly demonstrated an effect of¯uoxetine on insulin sensitivity in obese NIDDM subjects, achieving a reduction of the insulin EC 50 from 1351.8 to 1083 pmol Á L
71
. They could not show any effect of¯uoxetine on the maximal glucose uptake or V max . In contrast, 2 out of 3 insulin resistance indices reached statistical signi®cance at the higher insulin dose in our study. It is possible that this apparent contradiction is due to the shorter treatment used by Potter van Loon (2 vs 4 weeks in our study). It is however worth noting that more important effects were observed at the lower insulin dose. Even if receptor binding studies were not performed, our observations suggest, however, that¯uoxetine may improve insulin sensitivity by an effect on insulin binding to its receptor (decreased k m ) and also, to a lesser extent, by an action at a post-receptor site (increased V max ). Nevertheless, this assumption will have to be veri®ed with a different experimental approach.
The actual mechanism underlying the enhanced insulin sensitivity of peripheral tissues by¯uoxetine in obese NIDDM subjects still remains to be characterized. It has been reported that the serotonin agonist could centrally regulate the peripheral action of insulin. It has also been suggested 18 that the enhanced insulin action of such anorectic agents could be the result of a decrease in counterregulatory hormones. Scheen et al.
3 however, could not show any effect of d-fen¯uramine on counterregulatory hormones, but plasma catecholamine levels were not measured. It is also possible that the improved insulin action of these drugs could be due, at least in part, to their lowering effect on triglycerides and free fatty acids.
3,17 Finally, a direct stimulatory effect of fenuramine on glucose uptake and on glucose oxidation has been demonstrated in the isolated hemidiaphragm 19 and in human adipocytes. 20 It is worth noting that even if an improvement in glucose disposal was observed, neither plasma glucose, hemoglobin A 1c nor fasting plasma insulin changed over the 1-month treatment period. It is possible that a longer treatment period would have modi®ed these parameters favorably. In addition, it is likely that we would have seen a reduction in insulin levels if our study population had not been so dispersed for this particular variable.
In conclusion, our study reveals a direct action of uoxetine on insulin sensitivity independently of its anorectic effect. It is suggested that this enhancement of insulin sensitivity is due to an action at an insulin binding as well as post-receptor levels. The data indicate that the latter effect is predominant; it could be attributed either to a rise in the number of receptors or an increase in the af®nity of the receptor for its . Data are expressed as means AE s.e.m. *P`0.03 for changes during¯uoxetine versus placebo treatment. #P`0.04 for changes during¯uoxetine treatment compared to baseline.
Fluoxetine effect on insulin sensitivity? P Maheux et al ligand. Further studies are required to characterize this effect. Since¯uoxetine results in weight loss and improved insulin action, there is a rationale for the use of such a drug in the treatment of obese NIDDM subjects.
